A Brief Review of External Mass Balance and Internal Calcium Redistribution in Dialysis Patients—Is Calcium a Uremic Toxin?

2012 ◽  
Vol 22 (1) ◽  
pp. 186-190 ◽  
Author(s):  
Jochen G. Raimann ◽  
Stephan Thijssen ◽  
Nathan W. Levin
2018 ◽  
Vol 2018 ◽  
pp. 1-7 ◽  
Author(s):  
Radomír Hyšpler ◽  
Alena Tichá ◽  
Roman Šafránek ◽  
Petr Moučka ◽  
Zora Nývltová ◽  
...  

Indoxyl sulfate has been identified as a major factor in the dysregulation of several genes. It is classified as a poorly dialyzable uremic toxin and thus a leading cause in the poor survival rate of dialysis patients. A monocentric, prospective, open cohort study was performed in 43 male patients undergoing chronic renal replacement therapy in a single hemodialysis center. The aim of the study was to determine the influence of acetate- versus citrate-buffered dialysis fluids in hemodialysis (HD) and postdilution hemodiafiltration (HDF) settings on the elimination of indoxyl sulfate. Also, additional factors potentially influencing the serum concentration of indoxyl sulfate were evaluated. For this purpose, the predialysis and postdialysis concentration ratio of indoxyl sulfate and total protein was determined. The difference was of 1.15 (0.61; 2.10), 0.89 (0.53; 1.66), 0.32 (0.07; 0.63), and 0.44 (0.27; 0.77) μmol/g in acetate HD and HDF and citrate HD and HDF, respectively. Acetate HD and HDF were superior when concerning IS elimination when compared to citrate HD and HDF. Moreover, residual diuresis was determined as the only predictor of lower indoxyl sulfate concentration, suggesting that it should be preserved as long as possible. This trial is registered with EU PAS Register of Studies EUPAS23714.


2005 ◽  
Vol 21 (1) ◽  
pp. 138-144 ◽  
Author(s):  
Karin Moret ◽  
Jeroen Aalten ◽  
Warmold van den Wall Bake ◽  
Paul Gerlag ◽  
Charles Beerenhout ◽  
...  

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Diego Barbieri ◽  
ANDRÉS FELIPE DELGADO ◽  
Ana García-Prieto ◽  
Almudena Vega ◽  
Soraya Abad Esttebanez ◽  
...  

Abstract Background and Aims Retention of ß2microglobulin (ß2M), an uremic toxin in the middle molecular range, has been associated with cardiovascular morbidity and mortality in dialysis patients. Although ß2M levels are usually measured in hemodialysis patients, this practice is not common among peritoneal dialysis (PD) patients. The aim of this study is to evaluate the evolution of serum ß2M levels in incident PD patients. Method Prospective, observational study including incident PD patients in our hospital from January 2015 to October 2019. Patients with cardiorrenal syndrome or patients coming from hemodialysis were excluded. Serum ß2M levels were collected before starting PD and during follow up. Weekly KtV, residual renal function and cardiovascular events were also collected during follow up. Results We included 30 patients with a mean age of 57 +/- 17 years. 56.3% were male and 15.6% were diabetic. Mean follow up was 19.8 +/- 16.9 months. 18 patients were on continous ambulatory PD and 12 in automated PD. Mean serum ß2M levels before starting PD were 12.8 +/- 6.6 mg/l and they remained stable during follow up (12.9 +/- 5.2 mg/l, 15 +/- 4.2 mg/l, 14.3 +/- 6.9 mg/l, 10.2+/- 4.5 mg/l at month 6, 12, 24 and 36, respectively; p NS). No differences in serum ß2M levels were observed between continous ambulatory PD and automated PD. Serum ß2M levels were inversely and significantly correlated with weekly KtV (r= -0.943; p 0.009) and residual renal function (r= -0.829; p 0.042). One cardiovascular event was recorded during follow up. Conclusion Serum ß2M levels remain stable during follow up in our cohort of incident PD patients and is significantly and inversely correlated with weekly KtV and residual renal function. Serum ß2M levels monitoring could be helpful in these patients and would yield important information in this population.


2017 ◽  
Vol 32 (suppl_3) ◽  
pp. iii250-iii251
Author(s):  
Tomasz Kaminski ◽  
Malgorzata Karbowska ◽  
Krystyna Pawlak ◽  
Michal Mysliwiec ◽  
Lukasz Puchala ◽  
...  

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Fabiola Martin del Campo ◽  
Natali Vega Magaña ◽  
Noe A Salazar-Félix ◽  
Marcela Peña Rodríguez ◽  
María de Lourdes Romo-Flores ◽  
...  

Abstract Background and Aims Cognitive impairment is very common in dialysis patients, with negative effects on quality of life and mortality. In neurodegenerative conditions (Alzheimer, Parkinson) a gut-brain axis has been identified; however, there is no information about the relationship of gut microbiota alterations and presence of cognitive impairment in chronic kidney disease. The aim was to associate the gut microbiota profile with the cognitive function in patients on automated peritoneal dialysis (APD). Method Cross-sectional study in 39 APD patients; those with visual or mental disabilities, psychiatric or neurodegenerative diseases, inflammatory causes of ESRD, with active infections (including peritonitis), on anti-inflammatory drugs or antibiotics, were excluded. All patients had a clinical, biochemical, nutritional and dialysis adequacy evaluation, and were classified according to the presence of cognitive impairment using the Montreal Cognitive Assessment (MoCA) test. Fecal samples were collected and immediately stored at -80 ºC. DNA extraction was performed with Quick-DNA Fecal/Soil Microbe Miniprep Kit (Zymo Research). Subsequently, V3 and V4 regions of 16S rRNA were sequenced using illumina platform. Statistical analysis: Student t test and χ2 were used to compare quantitative and qualitative variables, respectively. Quantitative Insights Into Microbial Ecology (QIIME) pipeline and Linear Discriminant Analysis Effect Size (LEfSe) were employed for bioinformatic analysis. Results Eighty-two percent of subjects were male, mean age 47 ± 24 years, and dialysis vintage 11 (7-48) months. Sixty-four percent of patients had cognitive impairment. Patients with cognitive impairment were significantly older (53 ± 16 vs 38 ± 14, p=0.006), had higher frequency of diabetes mellitus (56% vs 21%, p=0.04), and had lower creatinine concentrations (11.3 ± 3.7 vs 14.9 ± 5.4, p=0.02) compared to patients with normal cognitive function. No differences were found in other biochemical, nutritional or dialysis adequacy variables. A total of 38,083 sequences per patient were obtained after the microbiome analysis. LEfSe analysis showed a preponderance of S24_7, Rikenellaceae, Odoribacteraceae, Odoribacter, and Anaerotruncus in patients with cognitive impairment. In contrast, patients without cognitive impairment were characterized by Dorea, Ruminococcus, Sutterella and Fusobacteria (LDA score (Log10) > 2.5; p < 0.05). Conclusion Cognitive impairment was present in two-thirds of these APD patients. Odoribacter and Anaerotruncus were significantly more abundant in patients with cognitive impairment than in those with normal function. Such gut bacteria might enhance cognitive impairment as have been described to increase the uremic toxin production and activation of inflammatory pathways in the central nervous system. This is the first study providing evidence than brain and behavior might be influenced by the gut-brain axis in dialysis patients.


2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Hideki Kawanishi

AbstractEvidence concerning online hemodiafiltration (ol-HDF) includes increased uremic toxin removal, prevention of dialysis-related hypotension, improved survival, and recovery of dialysis-related uncertain symptoms. In particular, evidence has been shown regarding prevention of dialysis hypotension and improvement of survival, but the mechanism of its manifestation is still unclear and its effects themselves are questionable. In Japan, pre dilution ol-HDF is mainly performed, and improvement in survival rate has been shown on the condition of convection volume is 40 L/session or more. In particular, the removal of α1-microglubulin (αMG), which is a medium-middle solute, is targeted. The antioxidant action (Heme Scavenger) of αMG, is presumed, but in dialysis patients, the majority in serum are deteriorated (oxidized) αMG. It has been pointed out that removing the deteriorated αMG by ol-HDF may produce new αMG from the liver and lead to recovery of the original antioxidant effect. However, clinical evidence of this mechanism is desired. Obtaining evidence for the indicated αMG removal activity of ol-HDF will lead to advancement in HDF.


Biochimie ◽  
2016 ◽  
Vol 126 ◽  
pp. 97-107 ◽  
Author(s):  
Alessandra F. Perna ◽  
Annarita Di Nunzio ◽  
Angela Amoresano ◽  
Francesca Pane ◽  
Carolina Fontanarosa ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document